Assoc Hospitaliere Nord Artois Clinique

At Assoc Hospitaliere Nord Artois Clinique in Valenciennes, the Service Oncologie is conducting clinical research focused on neoplasms, with a strong emphasis on non-small cell lung cancer and related advanced disease settings. These studies are designed to evaluate new treatment strategies, compare active therapies, and better understand how to improve outcomes for people with lung cancer.

• Studies in non-small cell lung cancer, including locally advanced, metastatic, and surgically treated disease
• Research in lung cancer with attention to treatment effectiveness and disease control
• Trials testing new combinations of immunotherapy and other anticancer treatments

Overall, this research aims to refine care for patients with difficult-to-treat lung cancers by comparing emerging therapies with current standards and exploring better ways to extend survival and improve response.

The site also contributes to studies in respiratory tract diseases, especially forms of lung cancer that affect the airways and lung tissue. The trials here are centered on evaluating whether newer treatment approaches can improve survival, reduce disease progression, and support better outcomes after surgery or in advanced stages.

• Research in advanced or metastatic non-squamous non-small cell lung cancer
• Trials for extensive-stage small cell lung cancer looking at ways to improve survival
• Studies in newly diagnosed and resectable NSCLC to assess treatment benefit after surgery

These studies reflect a broad effort to improve both first-line treatment and post-surgical care for patients with serious lung cancers, while also helping clarify which therapies offer the greatest clinical benefit.

Several trials at this hospital are exploring immunotherapy combinations for lung cancer, including comparisons between established treatments and newer investigational approaches. The purpose is to test whether adding novel agents can strengthen the immune response against cancer and improve disease control.

• Studies comparing pembrolizumab-based combinations with other treatment options
• Research evaluating atezolizumab and tiragolumab for safety and effectiveness
• Trials assessing whether newer immune-targeted therapies can improve survival outcomes

By focusing on immune-based treatment strategies, the site is helping advance care for patients whose cancers may benefit from more precise and potentially more durable treatment responses.

Another important area of research involves patients with resectable non-small cell lung cancer, where the goal is to improve outcomes after surgery. These studies are examining whether new treatment combinations can lower the risk of recurrence and strengthen long-term disease control.

• Trials in stage II, IIIA, and selected IIIB disease after resection
• Research focused on reducing the chance of cancer returning after surgery
• Comparisons of current standard care with newer anticancer therapies

This work supports a more personalized approach to early and locally advanced lung cancer, with the aim of improving recovery and long-term outcomes after curative-intent treatment.

The clinical trial portfolio also includes studies that compare one cancer treatment strategy against another, helping determine which options work best for specific patient groups. In neoplasms such as non-small cell lung cancer, these trials are important for identifying therapies that may offer better response rates or longer disease-free survival.

• Comparative studies of PD-1 inhibitor-based regimens in metastatic disease
• Trials assessing new combinations for KRAS G12C-mutated lung cancer
• Research evaluating treatment benefit in patients without known targetable mutations

By comparing different approaches head-to-head, the team at Assoc Hospitaliere Nord Artois Clinique contributes to evidence that can guide more effective and better-matched treatment choices for people living with lung cancer.